New! View global litigation for patent families

US2533065A - Micropulverized therapeutic agents - Google Patents

Micropulverized therapeutic agents Download PDF

Info

Publication number
US2533065A
US2533065A US73328047A US2533065A US 2533065 A US2533065 A US 2533065A US 73328047 A US73328047 A US 73328047A US 2533065 A US2533065 A US 2533065A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
tube
penicillin
therapeutic
air
invention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
George V Taplin
Frederick A Bryan
Original Assignee
George V Taplin
Frederick A Bryan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057Pumps therefor
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B05SPRAYING OR ATOMISING IN GENERAL; APPLYING LIQUIDS OR OTHER FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05BSPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B11/00Single-unit, i.e. unitary, hand-held apparatus comprising a container and a discharge nozzle attached thereto, in which flow of liquid or other fluent material is produced by the muscular energy of the operator at the moment of use or by an equivalent manipulator independent from the apparatus
    • B05B11/06Single-unit, i.e. unitary, hand-held apparatus comprising a container and a discharge nozzle attached thereto, in which flow of liquid or other fluent material is produced by the muscular energy of the operator at the moment of use or by an equivalent manipulator independent from the apparatus the spray being effected by a gas or vapour flow from a source where the gas or vapour is not in contact with the liquid or other fluent material to be sprayed, e.g. from a compressible bulb, an air pump or an enclosure surrounding the container
    • B05B11/062Single-unit, i.e. unitary, hand-held apparatus comprising a container and a discharge nozzle attached thereto, in which flow of liquid or other fluent material is produced by the muscular energy of the operator at the moment of use or by an equivalent manipulator independent from the apparatus the spray being effected by a gas or vapour flow from a source where the gas or vapour is not in contact with the liquid or other fluent material to be sprayed, e.g. from a compressible bulb, an air pump or an enclosure surrounding the container designed for spraying particulate material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/07General characteristics of the apparatus having air pumping means
    • A61M2205/071General characteristics of the apparatus having air pumping means hand operated
    • A61M2205/075Bulb type

Description

Dec. 5, 1950 G..v. TAPLIN Er AL MICROPULVERIZED THERAPEUTIC AGENTS Filed March 8, 1947 A sur! IN V EN TOR. GEORGE l( MPL/N FREDERICK A. BRYAN A TTORNEY Patented Dec. 5, 1,950

MICROPULVERIZED 'THERAPEUTIC AGENTS George V. Taplin and Frederick A. Bryan, Brighton, N. Y.

ApplicationMarc'n 8, 1947, Serial N0. 733,280

Claims. l

The present invention relates to therapeutic agents and to a method for administering the same. ln particular, the invention relates to absorbable therapeutic agents which vcan be produced in powdered form.

The invention is applicable .to the preparation and administration of .any absorbable therapeutic agent, such as, for instance, penicillin, streptomycin, any of the sulfonamides, adrenalin, Tuamine, Neosynephrine etc., whether used singly er in combination. For the purpose of an understanding the invention, however, it will be described specifically irst in vconnection with the preparation and administration .of penicillin. The wide variety of uses, to which the invention may be put will be pointed out more in detail hereinafter.

Hereteiore, one common way of administering penicillin has been by nebulizing a penicillin solution and inhaling the spray or vapor so produced. This method of administeringzpenicillin, which is known as the .aerosol principle, has,

however, many disadvantages.

`oxygen ymust be connected to the atomizer or nebulizer. While tanks of oxygen are relatively easy to procure in afhospital, they are hard to get for use in the home. Moreover, they are an expensive means for producing the pressure sufficient to form a spray. They add materially, also, to the weight and cumbersomeness of the nebulizer. Hand pumping, on the other hand, is a long, tedious operation. it may take Vonequarter to three-quarters of an hour to administer a treatment of the required number of units of penicillin with a manually operated spray. Even with the oxygen tank, it'takes 15 to 20 minutes to administer the required dosage. The length of time required to administer a dose is very tiring to the patient and often the irritation and nervous tension to which the patient is sub- Vjected during the long period required for administering the drug offsets to a large extent the benecial effects of the dosage.

Furthermore, the aerosol method 'of administration is inefficient and. wasteful. Fora treatment of twenty-ve thousand to'fty thousand units of penicillin, fty thousand to one hundred thousand units may have to :be employed; so

-much of the penicillin-is dissipated vand lost in the air in the spray. In order that the patient Amay obtain the required numberof units of penicillin in a day,then, fourmor five vdoses per day may have to be administered.

A further drawback of the aerosol method of administration is the instability of penicillin in solution. Penicillin solutions deteriorate rapidly, and must be kept refrigerated to vretain their full potency for even a week.

.One object of the present invention is tozprovide a new form in which therapeutic agents, such as penicillin, can be produced, to enable lsuch substances to be :administered much more rapidly and much more eiciently than heretofore.

Another object of the invention is to provide a yform in which therapeutic agents may be administered, which will be stable and which can with ease be so preserved as to retain more or less indefinitely the potency of the agent.

Another object of the invention is to provide a simple method for administering therapeutic substances whereby the required :dosage can be supplied in an extremely short period oi time, and eortlessly so'far as .the patient is concerned.

:A further object of the invention is to provide simple, inexpensive apparatus for administering therapeutic agents in powdered form.

Still anotherfobject of the invention is to provide a piece of apparatus for administering theraeutic substances, which will be light in weight and of a size that can readily be carried-around in the pocket of a patient.

A still further object of the invention is to provide a piece of apparatus for administering therapeutic substances, which is simple in construction, quite inexpensive, and which can readily be operated by the patient himself without eifort.

Other objects ofthe invention willbe apparent hereinaiter from the specication and fromthe rec-ital of the appendedclaims.

lt is well known that penicillin can be produced in crystalline form, but heretofore the-crystals of penicillin have been dissolved in a saline solution and the penicillin administered, as already described, in the form of a vapor. Thepresent invention is based on the use of penicillin and other soluble therapeutic agents in the formof powder, and upon the administration of the agent by particulate suspensionof the agent in air, Vso that a powder smokeis produced, which can be Vinhaled or applied topically. The'powdered penicillin can rbe obtained by grinding crystalline penicillinin a ball-mill or other suitable apparatus to a powder with Aa.particulate-size of less than one micron. Thus the powder particles are of the approximate size or may be even smaller than the size of the droplets produced by a nebulizer.

It has been found that when micro-pulverized penicillin is administered by particulate suspension in air, a dose of twenty-ve thousand to ty thousand units ci penicillin can be administered in one or two minutes or less. Moreover, the powdered penicillin can easily be carried in an air stream produced by simple inhalation through the mouth or by pressure on an ordinary rubber air bulb. The administration of the penicillin or other therapeutic agent in the novel form of the present invention can be effected therefore without effort; and there is no need for the use of oxygen or any other mechanical source or pressure. It has been found, too, that when penicillin is administered in this way, the eiiciency of 'the dosage is 93 to 95 per cent, so that the cost and the number oi dosages are reduced very considerably from those heretofore required.

Moreover, since there are seventy square meters of surface in the lungs, the very line particles of penicillin supplied to the lungs by the present method are absorbed quickly and over so great an area that a dosage or" penicillin administered according to the present invention is extremely effective, so that the disease, for which the dosage of penicillin is prescribed, can be brought under control much more quickly than by previous methods oi administration. Aside from the local action of the penicillin on the lungs, it is picked up quickly by the blood stream.

Because of the high potency or" pure penicillin, it has been found desirable in practice to mix the penicillin with anhydrous glucose or a similar Vehicle in the proportion of 1 5 to 1 26 and to grind the mixture together to a powder. This mixture provides an inexpensive, but eiective therapeutic agent, and when inhaled in the form of a smoke produces practically no bronchial irritation, while the taste is a mixed one of faint bitterness and sweetness. Because of its glucose content, moreover, the mixture is additionally benecial to a patient.

In the apparatus for administering the powdered penicillin, it is desirable to provide two chambers, which are connected together. In the rst of these chambers, which is that through which the air passes first, there is provided some substance which will absorb the moisture out of the air, so that the air will be dry when it passes into the second chamber, which contains the penicillin powder. This moisture absorbing substance may be anhydrous calcium sulfate or a similar substance, and this may be mixed with a litmus-type indicator which will show by change of color when the dehydrating material has picked up all of the moisture it can hold. Various such materials are well known and are sold extensively under different trade-names.

It is also within the contemplation of the invention, however, to use a disposable container containing a single specic dose of the therapeutic agent. This container, which may be made of papier-mache', is provided with inlet ducts through which air is admitted to the powder chamber and an outlet duct through which the powder in suspension may be inhaled through the nose or mouth. The container is intended to be sold with the dose in it and with the dose protected against moisture by an airtight covering which encloses the whole container. This covering is ripped away when the dose is to be used, and the container is intended to be thrown away after use.

In the drawings:

Fig. 1 is a sectional view of a piece of apparatus built according to one embodiment of this invention for administering a therapeutic agent, and having an air bulb for producing the air stream that picks up the therapeutic powder;

Fig. 2 is a sectional view of the apparatus shown in Fig. 1, but illustrating how, by removal of the air bulb, the apparatus may be employed for inhaling the therapeutic substance through the mouth;

Fig. 3 is a sectional view, showing how the apparatus of Figs. 1 and 2 may be adapted for use with a face mask;

Fig. 4 is a perspective View showing a pressure cuff such as may be employed around the chest of a patient in a weak, or comatose condition, to produce the air stream;

Fig. 5 is a section on the line 5 5 of Fig. 4;

Fig. 6 is a sectional View of a piece of apparatus built according to the present preferred embodiment of this invention; and

Fig. 7 is a sectional View of a disposable combined container and inhaler made according to one embodiment of this invention.

Fig. 1 shows a Very simple form of apparatus constructed according to this invention for administering a powdered therapeutic agent. Here, Iii denotes a container that may be made of glass or of a suitable plastic. The open end of this container is closed by a rubber stopper ll. This stopper has two holes in it. Through one of these holes there passes a tube l2, which extends downwardly a considerable distance into the container. This tube is formed exteriorly oi the container with an enlarged portion forming a chamber lli, and beyond this chamber the tube terminates in a reduced end portion l5. The tubular end I6 of a suitable rubber air pressure bulb Il may be connected to the end l5 of the tube as shown in Fig. 1. Through the other hole in the stopper Il, there passes a tube 29, which has its end turned at an angle below the stopper l I, as denoted at 2 l. Exteriorly of the container, this tube 2Q is formed with an enlarged portion 22, and it terminates in a reduced end portion 23. The enlarged portion 22 of the tube 2? has an opening 24 formed in one side thereof, to provide an air vent. The tubes l2 and 2e may be made of glass, or of plastic, or of a suitable metal, such as copper.

The therapeutic agent, which is to be used, which may be, for instance, finely powdered penicillin, whose particulate size is one micron or less, or which may be powdered penicillin mixed with powdered glucose or starch in the form of a micropulverized powder, is placed in the container l0, being denoted at P. A suitable dehydrating substance, such as anhydrous calcium sulfate, denoted at D, is placed in the chamber I4 of tube I2. This preferably is employed in the commercial form in which it is mixed with a litmus agent so that it will turn from blue to pink, when it has picked up all the moisture which it can.

In use, if a person wants to administer the penicillin, or other therapeutic agent to a patient, or if the patient wishes to administer it to himself, the end 23 of tube 2U may be placed one nostril of the patient, and the bulb l1 is alternately squeezed and released. Thus, a stream of air, is forced through the dehydrating substance D, down through the tube i2 into the container l0. The pressure of this air, forces the powder P in the container up through the substance to a patient.

secured to it at any suitable point.

fats-afoot tube 520 and 'ou-t through the end 23 this tube fa -forin like smoke; and the patient inhal'es this therapeutic smoke. A baffle 25 is secured in any vsuitable manner Vto the tube i2 some distance above the lower end thereof, so as to prevent the powder P from being expelled from the container in lumps or gobs. These might irritate the throat, and would be wasteful of the medicine. The baffile isl'circular and there is but a -slig-ht diierence 'between the diameter of the baiile and the internal diameter of the container, so that the only vway in which the particles of powdered penicillin `can lreach the tube 26 is around the periphery of Ythe baille.V

The Vent 24 in the tube 2t admits of Jan additional `current of air being drawn `into the tube 26 as thestream of powder and air passes through that tube. This additional air stream serves to keep lthe powder stirred up and agitated and `further insures that it will pass out of the end '23 of the tube 28 in the desired form of smoke.

Il 'the Vent were not provided, too much powder might be expelled from the end 23 of the vtube atone time; and this would be wasteful.

The same piece of apparatus shown in Fig. l can be used without change for inhaling the penicillin, or other therapeutic agent, through the mouth. Thus, after removing the tube It 'and air pressure bulb il, the patient, part of whose head is denoted at H in Fig. 2, can place the end 23 of the tube '26 in his mouth M and vsuck Iair through the end i5 of the tube i2, through the dehydrating substance D, into the container H3, and thence draw the vpowder suspended in air through the tube 2t into his mouth. In this case, an additional current of air is usually `not required, and the patient can close the vent 24with his thumb.

`The same piece of apparatus can be used, also,

without substantial change, in connection with a face mask where it is desirable to employ `such a mask in the administration of a rtherapeutic In this case, the end 23 o f tube 23 is inserted into an opening Vformed on the projecting portion 36 of the face mask M (Fig. 3), and there is a rubber fla-p valve 3! 4applied over the end 23 of tube 26. The face mask itself, which is shaped to t the contour of the face, has a further rubber iiap valve 32 The rubber 'ap valve 3l permits or" the powdered penicillin and air being drawn into the face mask as the patient inhales. It closes when the patient ex- The rubber flap valve 52 yallows of the air being exhausted from the mask when the patient 'exhales lWhen a patient is in a weak or comatose condition, or lacks the power of coordination, the

"air pressure for forcing the powder out of the container may be supplied by the movement of "the patients chest `as he alternately inhales and exhales. Thus, a pressure cud, such as denoted atS in Fig. 4, may be fastened around the chest of the patient by webbed straps 35 and 36. These straps are secured to opposite ends of the l.pressure cu and may be fastened together at )valve litl mounted therein. which` is normally pressed to closed 'position by la 'coil spring 4'2. The tube 39 is adapted to have its vend 53 -con'- nected to the end l5 of the tube t2 of the appa ratus shown in Fig. l, in place of 'the tube i6 and air pressure bulb Il. This tube `r39 hfas a `ball check Valve fili mounted therein, which is adapted to be pressed to closed position by a coil spring 55.

The pressure cuff is adapted to be secured 'to the patient when the patients chest is fully expanded, that is, at full inspiration, and when Vthe springs 3l are fully collapsed by the pressure of the patients chest on the pressure cuil. `As the patient eXhales, the springs expand, 'and the Valve lil opens, allowing the bag 35 to fill with air. When the patient inhales, the chest expands; the valve El is closed; and the air is forced out of the bag 35 through the valve '41%, which is opened by the pressure of this air, and into the end l5 of tube i2. Thus, the movement of the patients chest will'operate the apparatus of this invention and supply him with the lthere;- peutic agent in the form of smoke so that he can inhale it into his lungs. A nose clip may be necessary to secure the end 23 of the tube 4'2G in position so that the patient can lbreathe ythe smoke in through his nose.

The present preferred form of apparatus for dispensing therapeutic substances according to the invention is disclosed in Fig. 6. This oom'- prises a tube 50 made of glass or plastiofone end of which is closed by a bottom cap piece 5|. If the tube 55 is made of plastic, this cap piece may be made of plastic, also, and it may be secured in the tube 5i! simply by friction. Secured in the tube 50 by friction or in any other suitable manner, about midway of the height of the tube is a partition member 52. This divides the tube 50 into a lower and an upper chamber. The lower chamber is adapted to contain the vdehydrating agent D. The partition member 52 has a lcentral opening or duct 53 formed therein. On top of the partition member 52, there is placed a thin layer of ne glass wool 513 which acts as a filter. On top of this layer of glass wool, within the 'tube 50, there is mounted a cup-shaped member 55. This is adapted to hold the powdered therapeutic agent P. There are several equi-spaced holes 56 drilled longitudinally in the sidewall of the cup-shaped member 55 from the bottom 'of the cup-shaped member upwardly for the greater portion of the height thereof. These holes or ducts 56 communicate with short, helically arranged ducts 51, which lead into the interior of the cup. There is a gasket 58 placed on top of the cup 55, and the cup is secured in the tube 50 by the upper cap member it which threads into the tube 5i). The cap member 6e has a central opening therein, and in this there is mounted a short tube or duct 6l. The bottoms oi the cap member 60 and of the tube 5| are made to spherical shape, as denoted at 62, so as to provide a dome-like or sphericaltop for the chamber in which the powder P is contained.

There is a right angular duct drilled or otherwise formed in the bottom end cap 5|, and there is a short .tube 66 mounted at one side in this end cap to communicate with the duct 65. An air pressure bulb 6l, having an engaging portion 68 may be secured to the tube 65, by pushing the portion 68 over the outside of the tube 66.

To use the apparatus of Fig. 6, the patient alternately squeezes then releases the bulb 6?, thissforces air through the tube` 66, :and duct `6,5

into the lower chamber containing the dehydrating substance D. The dehydrating substance removes the moisture from the air. The dried air passes out of the lower chamber through the duct 53 in the partition member 52, and through the filter 54 into the ducts 5e formed in the cupshaped member 55. Thence it flows through the ducts into the interior of this cup. The helical inclination of the ducts 57 causes air flowing into the upper chamber to create a turbulence and force the powder into a spiral path. The spherical dome 62 of the upper chamber helps keep the powder agitated. From the upper chamber the air-borne powder is forced upwardly through the opening in the tube 6| to the outer air where it emits in the form of smoke.

The upper chamber of the apparatus is of reduced area because of the use of the cup 55. The small surface area increases the emptying einciency of the powder chamber. The outlet tube BI is likewise made of small internal calibre to reduce the amount of precipitate on the walls ci the tube. The threaded connection of the upper end cap 6U with the tube 50 prevents the powder from seeping out between the tube 5B and the end cap, the thread serving, therefore, as a seal.

The apparatus shown in Fig. 6v is adapted to all the various uses of the apparatus shown in Figs. 1 to 5 inclusive. On removing the bulb 67, the outlet tube 6i can be placed in the mouth, and the powder drawn directly into the oral cavity. The outlet tube 6i can also be connected to a face mask, in a manner similar to the connection between the outlet tube 2B of Fig. 3 and the face mask of that gure, or, if desired, the outlet tube 6l can be replaced by a right angular tube for this purpose. The bulb 6'! can be replaced by a pressure cuff, such as shown in Figs. e and 5. Various adapters can also be tted to the outlet tube, for nasal, oral, dental, vaginal use, etc., if desired.

In some cases it may be desirable to provide an inhaler which contains a single dose of the therapeutic agent, which is to be administered, and which is disposable after use. Such an inhaler is shown in Fig. '7. This comprises a cylindrical-shaped cup or barrel it, and a cap il.

The cup or barrel is hollowed out to receive a measured dose of the therapeutic powder P. Ducts 'l2 are formed in the sidewall of the cup or barrel from the bottom 'i3 thereof to a point above the level of the powder P in the container. These ducts 'I2 communicate with helical ducts M that lead into the interior of the container above the level of the powder.

The cap l l, which tapers externally upwardly, has a single axial duct l5 formed therein.

The barrel and cap may be made of papiermache or of a suitable plastic. The measured dose is placed in the container and the cap sealed thereon. Then container and cap are dipped in some suitable sealing material or wrapped in a suitable cellulose cover so as to completely seal and cover the whole container. This sealing covering is designated at 76 in Fig. '7. Strings or wires 11 and 'i8 may be embedded in this covering so that when they are pulled, the part of the covering, which covers the outside end of duct l5, and the part of the covering, which covers the bottom or outside ends of ducts l2, are removed. Then the inhaler is ready for use` In use, the patient simply puts the small end of the cap 'Il into a nostril or into his mouth and inhales. Air is drawn through the ducts 12 and 'I4 into the powder chamber; the helical shape of the ducts creates a turbulence in the powder; and the powder in suspension is drawn up through the duct 15 into the nostril or mouth.

The principle of administering soluble, absorbable therapeutic agents in a micro-pulverized state, suspended in air with or without a vehicle, by inhallation is a new method of therapeutics. It may be applied to penicillin in the crystalline or amorphous state. It may be used as already indicated for the administration of any other absorbable therapeutic agent such as streptomycin and the sulfonamides, either separately or in combination. All of the antibiotic agents such as the sulfonamides, and streptomycin are now available in crstalline form; and in the crystalline state they are stable so long as they are kept in moisture-free containers. In addition, the invention may be used for the administration of insulin and other hormones, such as estrone, progesterone, testosterone, desoxycorticosterone, or for the administration of any of the antihistamine group of drugs in the treatment of hay fever, hives, etc., or in the administration of pituitrin, or of the vasoconstrictors, such as Neosynephrina Tuarnine, adrenalin, ephedrin, Privin'e, Paredrine, etc., or it may be used in the application of heparin. In case of administration of drugs of the antihistamine group, the present invention is much more eiective than previous methods of treating hay fever and other allergies through hypodermic injections. With the method of the present invention the therapeutic agent is supplied directly to the nose and lungs, and does not have to be absorbed into the blood stream to begin to work.

The above named drugs can be given individually or in combination as indicated, and may be combined in a vehicle which will allow either rapid or slow absorption as desired. The drugs furthermore, may be combined with the vehicle either physically or chemically, and many combinations may be devised to t particular needs.

The equipment and therapeutic agent may also be used for topical administration, such as for dusting open wounds, burns, otitis externa, abdominal wounds, vaginal and rectal infections, surgical wounds, etc.; and the use of the method and apparatus is not limited to inhalation procedures alone. Heretofore, for instance, in administering penicillin, streptomycin, tyrothricin, and similar substances to open wounds, they have simply been thrown into the wound. With the apparatus and method of present invention, the substance can be applied more thoroughly to the wound or burn, and more efciently. The smoke penetrates to every part of the area to be treated and is much more effective than merely scattering the therapeutic agent over the surface.

There are certain diseases in the treatment of which this new method -of therapy is particularly advantageous. In principle, they are the diseases where a high concentration of therapeutic agent at the surface of the infection or reacting organ is of special importance. Thus, the present method of therapy may be used in the treatment of diseases of the respiratory tract caused by organisms sensitive to the available antibiotics including such diseases as: tonsillitis, Vincents angina, infected tooth sockets, diphtheria, otitis media, sinusitis, laryngitis, tracheitis, bronchitis, pneumonia, bronchiectasis, and tuberculosis. Moreover, the invention is applicable in cases of disease carriers, particularly in such cases as meningococcus, Streptococcus, diphtheria, and pneumococcus. It may be used.

also, in the treatment of urinary infection particularly by use of streptomycin.

In addition, the principle of treatment involved in this invention provides a means of admnistration of various therapeutic agents that can be used on ambulatory patients for the venereal diseases such as gonorrhea, syphilis, chancroid, and lymphagranuloma. It can also be used for treatment of rheumatic fever. In this last-named case, sulfonamides or penicillin may be continuously administered for treatment of hemolytic streptococcal infections. The invention may be employed, also, in the treatment of meningitis, scarlet fever, pneumonia, diphtheria and streptococcal diseases in hospitals, barracks, and closely-knit communities; and for the prevention of post-operative pulmonary infections by pre-operative sterilization of the respiratory tract by use of the various antibiotics singly or in combination as indicated by the bacterial flora present.

This invention provides a ynew principle of therapeutics through which numerous specific drugs may be administered in micro-pulverized state, suspended in air, with or without a vehicle. The apparatus constructed according to the invention is simple to operate, inexpensive, enicient, fool-proof, and measured doses of various therapeutic agents may be administered by it in the hospital or at home in a period of two to ve minutes without any of the disadvantages of the previous method of administration of such substances.

While the invention has been described in connection with particular embodiments and particular uses thereof, it will be understood that 1t is capable of various further modifications and uses, and that this application isl intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth and as fall within the scope of the invention or the limits of the appended claims.

Having thus described our invention, what we claim is:

1. A therapeutic agent for direct administration to humans by inhalation comprising dry, micropulverized, powdered penicillin having a particulate size in the order of one micron.

2. A therapeutic agent for direct administration to humans by inhalation comprising a dry,

1o micropulverized, powdered, soluble antibiotic substance, from the group consisting of penicillin and streptomycin which are produced by microorganisms, the particulate size of the micropulverized substance being in the order of one micron.

3. A therapeutic agent for direct administration to humans. by inhalation comprising dry, micro-pulverized, powdered streptomycin having a particulate size in the order of one micron.

4. A therapeutic agent for direct administration to humans by inhalation comprising dry, micropulverized, powdered crystals of a soluble antibiotic substance, from the group consisting of penicillin and streptomycin which are produced by micro-organisms, the particulate size of the micropulverized crystals not exceeding one micron.

5. A therapeutic agent for direct administration to humans by inhalation comprising a dry, micropulverized, powdered mixture of glucose and a soluble antibiotic substance from the group consisting of penicillin and streptomycin which are produced by micro-organisms, the particulate size of said mixture being in the order of one micron.

GEORGE V. TAPLIN. FREDERICK A. BRYAN.

REFERENCES CITED The following references are of record in the le of this patent:

UNITED STATES PATENTS Number Name Date 236,071 Olcott Dec. 28, 1880 2,156,378 Denny et al. May 2, 1939 2,185,927 Shelanski Jan. 2, 1940 2,214,032 Stewart Sept. 10, 1940 2,414,918 Abramson Jan. 28, 1947 OTHER, REFERENCES Surgery, Dec. 1944, pages 937 and 938.

The Pharmaceutical Journal (London) Feb. 8, 1941, page 40.

Science, July 14, 1944, pages 33-35.

Science, Sept. 7, 1945, pages 255 and 256.

J. A. M. A., May 23, 1942, pages 324 to 327.

J. A. M. A., Apr. 25, 1942, page 1514.

Proc. Soc. Exptl. Biol. and Med., Oct. 1943. pages 8 to 10.

British Medical J., Aug. 16, 1941, page 221.

Int. Abstract Surgery, July 1943, pages 79 and 80.

The Lancet (London), Dec. 16, 1944, page 775.

Claims (1)

1. A THERAPEUTIC AGENT FOR DIRECT ADMINISTRATION TO HUMANS BY INHALATION COMPRISING DRY, MICROPULVERIZED, POWDERED PENICILLIN HAVING A PARTICULATE SIZE IN THE ORDER OF ONE MICRON.
US2533065A 1947-03-08 1947-03-08 Micropulverized therapeutic agents Expired - Lifetime US2533065A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US2533065A US2533065A (en) 1947-03-08 1947-03-08 Micropulverized therapeutic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2533065A US2533065A (en) 1947-03-08 1947-03-08 Micropulverized therapeutic agents
US2693805A US2693805A (en) 1947-03-08 1949-11-26 Apparatus for administering therapeutic agents

Publications (1)

Publication Number Publication Date
US2533065A true US2533065A (en) 1950-12-05

Family

ID=24946951

Family Applications (1)

Application Number Title Priority Date Filing Date
US2533065A Expired - Lifetime US2533065A (en) 1947-03-08 1947-03-08 Micropulverized therapeutic agents

Country Status (1)

Country Link
US (1) US2533065A (en)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2741573A (en) * 1953-12-28 1956-04-10 Abbott Lab Penicillin compositions for intramuscular injection
US2798836A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Inhalable live virus veterinary vaccine
US2798835A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Newcastle disease and infectious bronchitis vaccines and production thereof
US2802772A (en) * 1954-09-09 1957-08-13 Merck & Co Inc Aerosols compositions; bomb, and process for treating flocks of chickens
US2861024A (en) * 1957-11-12 1958-11-18 Merck & Co Inc Antibiotic dusts
US2872375A (en) * 1955-03-21 1959-02-03 Lepetit Spa Stabilized penicillin salts
US2959325A (en) * 1954-04-29 1960-11-08 Risdon Mfg Co Method and apparatus for dispensing dry powders
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
US3653380A (en) * 1970-02-16 1972-04-04 American Cyanamid Co Aerosol powder dosage dispensing device
US3809084A (en) * 1970-02-16 1974-05-07 American Cyanamid Co Pressurized portable dispenser
US3888252A (en) * 1974-01-23 1975-06-10 Anthony J Side Powder inhaler
US4921488A (en) * 1988-01-15 1990-05-01 Maitz Carlos A Aspirator device for body fluids
EP0404454A1 (en) * 1989-06-21 1990-12-27 FISONS plc Disposable medicament inhalation device
EP0407276A2 (en) * 1989-07-04 1991-01-09 VALOIS Société Anonyme dite: Dispensing and pulverizing apparatus for a dose of a divisible product
WO1993011746A1 (en) * 1991-12-10 1993-06-24 Boehringer Ingelheim Kg Inhalation powders and method of manufacturing them
US5239991A (en) * 1989-06-21 1993-08-31 Fisons Plc Disposable powder medicament inhalation device with peel-off cover
US5747002A (en) * 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6136295A (en) * 1996-05-24 2000-10-24 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6153224A (en) * 1995-01-31 2000-11-28 Co-Ordinated Drug Development Limited Carrier particles for use in dry powder inhalers
US6221338B1 (en) 1993-10-26 2001-04-24 Vectura Limited Method of producing particles for use in dry powder inhalers
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US6543448B1 (en) 1994-09-21 2003-04-08 Inhale Therapeutic Systems, Inc. Apparatus and methods for dispersing dry powder medicaments
US20030125236A1 (en) * 2000-12-29 2003-07-03 Advenced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
US6620132B1 (en) * 1996-01-11 2003-09-16 Joseph I. Skow Surgical irrigation device
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US6679256B2 (en) 1999-12-17 2004-01-20 Nektar Therapeutics Systems and methods for extracting powders from receptacles
US6681767B1 (en) 1991-07-02 2004-01-27 Nektar Therapeutics Method and device for delivering aerosolized medicaments
US20040062718A1 (en) * 1996-05-24 2004-04-01 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US7048908B2 (en) 2000-12-29 2006-05-23 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
EP1685866A2 (en) * 1998-06-04 2006-08-02 Nektar Therapeutics Dry powder dispersing apparatus and methods for their use
EP1693080A2 (en) * 1991-07-02 2006-08-23 Nektar Therapeutics Method and device for delivering aeroslized medicaments
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20140096770A1 (en) * 2012-10-05 2014-04-10 Lily A. Neff Salt puffer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US236071A (en) * 1880-12-28 Catarrh remedy
US2156378A (en) * 1939-01-18 1939-05-02 James J Denny Method of neutralizing the condition producing qualities of finely pulverized silicious materials
US2185927A (en) * 1937-02-16 1940-01-02 Herman A Shelanski Insufflator
US2214032A (en) * 1939-06-23 1940-09-10 Walter B Stewart Apparatus for administering powdered aluminum
US2414918A (en) * 1941-09-23 1947-01-28 Abramson Harold Alexander Solutions for the improved nebulization therapy of the lungs and bronchioles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US236071A (en) * 1880-12-28 Catarrh remedy
US2185927A (en) * 1937-02-16 1940-01-02 Herman A Shelanski Insufflator
US2156378A (en) * 1939-01-18 1939-05-02 James J Denny Method of neutralizing the condition producing qualities of finely pulverized silicious materials
US2214032A (en) * 1939-06-23 1940-09-10 Walter B Stewart Apparatus for administering powdered aluminum
US2414918A (en) * 1941-09-23 1947-01-28 Abramson Harold Alexander Solutions for the improved nebulization therapy of the lungs and bronchioles

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2741573A (en) * 1953-12-28 1956-04-10 Abbott Lab Penicillin compositions for intramuscular injection
US2798836A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Inhalable live virus veterinary vaccine
US2798835A (en) * 1954-01-18 1957-07-09 American Cyanamid Co Newcastle disease and infectious bronchitis vaccines and production thereof
US2959325A (en) * 1954-04-29 1960-11-08 Risdon Mfg Co Method and apparatus for dispensing dry powders
US2802772A (en) * 1954-09-09 1957-08-13 Merck & Co Inc Aerosols compositions; bomb, and process for treating flocks of chickens
US2872375A (en) * 1955-03-21 1959-02-03 Lepetit Spa Stabilized penicillin salts
US2861024A (en) * 1957-11-12 1958-11-18 Merck & Co Inc Antibiotic dusts
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
US3809084A (en) * 1970-02-16 1974-05-07 American Cyanamid Co Pressurized portable dispenser
US3653380A (en) * 1970-02-16 1972-04-04 American Cyanamid Co Aerosol powder dosage dispensing device
US3888252A (en) * 1974-01-23 1975-06-10 Anthony J Side Powder inhaler
US4921488A (en) * 1988-01-15 1990-05-01 Maitz Carlos A Aspirator device for body fluids
EP0404454A1 (en) * 1989-06-21 1990-12-27 FISONS plc Disposable medicament inhalation device
US5239991A (en) * 1989-06-21 1993-08-31 Fisons Plc Disposable powder medicament inhalation device with peel-off cover
EP0407276A2 (en) * 1989-07-04 1991-01-09 VALOIS Société Anonyme dite: Dispensing and pulverizing apparatus for a dose of a divisible product
EP0407276A3 (en) * 1989-07-04 1991-11-27 Valois Societe Anonyme Dite: Dispensing and pulverizing apparatus for a dose of a divisible product
EP1693080A2 (en) * 1991-07-02 2006-08-23 Nektar Therapeutics Method and device for delivering aeroslized medicaments
US6681767B1 (en) 1991-07-02 2004-01-27 Nektar Therapeutics Method and device for delivering aerosolized medicaments
EP1693080A3 (en) * 1991-07-02 2007-07-25 Nektar Therapeutics Method and device for delivering aeroslized medicaments
US5478578A (en) * 1991-12-10 1995-12-26 Boehringer Ingelheim Kg Powders for inhalation
WO1993011746A1 (en) * 1991-12-10 1993-06-24 Boehringer Ingelheim Kg Inhalation powders and method of manufacturing them
DE4140689B4 (en) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalation powders and methods for their preparation
US20030202944A1 (en) * 1993-10-26 2003-10-30 Vectura Limited Carrier particles for use in dry powder inhalers
US6221338B1 (en) 1993-10-26 2001-04-24 Vectura Limited Method of producing particles for use in dry powder inhalers
US8137657B2 (en) 1993-10-26 2012-03-20 Vectura Limited Carrier particles for use in dry powder inhalers
US6582678B2 (en) 1993-10-26 2003-06-24 Vectura Limited Carrier particles for use in dry powder inhalers
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US6543448B1 (en) 1994-09-21 2003-04-08 Inhale Therapeutic Systems, Inc. Apparatus and methods for dispersing dry powder medicaments
US7011818B2 (en) 1995-01-31 2006-03-14 Vectura Limited Carrier particles for use in dry powder inhalers
US6521260B1 (en) 1995-01-31 2003-02-18 Vectura Limited Carrier particles for use in dry powder inhalers
US8920781B2 (en) 1995-01-31 2014-12-30 Vectura Limited Carrier particles for use in dry powder inhalers
US20030170183A1 (en) * 1995-01-31 2003-09-11 Vectura Limited Carrier particles for use in dry powder inhalers
US6153224A (en) * 1995-01-31 2000-11-28 Co-Ordinated Drug Development Limited Carrier particles for use in dry powder inhalers
US7718163B2 (en) 1995-01-31 2010-05-18 Vectura Limited (01696917) Carrier particles for use in dry powder inhalers
US20100330188A1 (en) * 1995-01-31 2010-12-30 Vectura Limited Carrier particles for use in dry powder inhalers
US5747002A (en) * 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US6620132B1 (en) * 1996-01-11 2003-09-16 Joseph I. Skow Surgical irrigation device
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US6399102B1 (en) 1996-05-24 2002-06-04 The Penn State Research Foundation Aerodynamically light particles for pulmonary drug delivery
US7628977B2 (en) 1996-05-24 2009-12-08 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20040047811A1 (en) * 1996-05-24 2004-03-11 The Penn State Research Foundation Aerodynamically light particles for pulmonary drug delivery
US20040062718A1 (en) * 1996-05-24 2004-04-01 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6635283B2 (en) 1996-05-24 2003-10-21 Penn State Res Found Aerodynamically light particles for pulmonary drug delivery
US20050158249A1 (en) * 1996-05-24 2005-07-21 Edwards David A. Aerodynamically light particles for pulmonary drug delivery
US6942868B2 (en) 1996-05-24 2005-09-13 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6136295A (en) * 1996-05-24 2000-10-24 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20080253971A9 (en) * 1996-05-24 2008-10-16 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20070014738A1 (en) * 1997-09-15 2007-01-18 Edwards David A Particles for inhalation having sustained release properties
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
EP1685866A2 (en) * 1998-06-04 2006-08-02 Nektar Therapeutics Dry powder dispersing apparatus and methods for their use
US6901929B2 (en) 1998-06-04 2005-06-07 Nektar Therapeutics Dry powder dispersing apparatus and methods for their use
US6546929B2 (en) 1998-06-04 2003-04-15 Inhale Therapeutic Systems, Inc. Dry powder dispersing apparatus and methods for their use
EP1685866A3 (en) * 1998-06-04 2013-07-10 Nektar Therapeutics Dry powder dispersing apparatus and methods for their use
US7422013B2 (en) 1998-06-04 2008-09-09 Nektar Therapeutics Dry powder dispersing apparatus and methods for their use
US8161969B2 (en) 1998-06-04 2012-04-24 Novartis Ag Dry powder dispersing apparatus and methods for their use
US20030209243A1 (en) * 1998-06-04 2003-11-13 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6679256B2 (en) 1999-12-17 2004-01-20 Nektar Therapeutics Systems and methods for extracting powders from receptacles
US20030125236A1 (en) * 2000-12-29 2003-07-03 Advenced Inhalation Research, Inc. Particles for inhalation having rapid release properties
US20080039366A1 (en) * 2000-12-29 2008-02-14 Advanced Inhalation Research Particles for inhalation having sustained release properties
US7048908B2 (en) 2000-12-29 2006-05-23 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
US7384649B2 (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US20140096770A1 (en) * 2012-10-05 2014-04-10 Lily A. Neff Salt puffer
US9764103B2 (en) * 2012-10-05 2017-09-19 Lily A. Neff Salt puffer

Similar Documents

Publication Publication Date Title
US3455294A (en) Respiratory device
Barach The use of helium in the treatment of asthma and obstructive lesions in the larynx and trachea
Rau The inhalation of drugs: advantages and problems
US3815606A (en) Endotracheal catheter
US3897779A (en) Triamcinolone acetonide inhalation therapy
US7305986B1 (en) Unit dose capsules for use in a dry powder inhaler
US4706683A (en) Method and apparatus for bolus delivery of gases and aerosols and insufflations
Dekker et al. Conditioning as a cause of asthmatic attacks: A laboratory study
US4121583A (en) Method and apparatus for alleviating asthma attacks
Jacoby et al. Transtracheal resuscitation
US4803977A (en) Method and apparatus for the diagnosis of respiratory diseases and allergies
US3565071A (en) Self-regulating therapeutic inhaler
Newman et al. Therapeutic aerosols 1--physical and practical considerations.
US5752502A (en) General purpose aerosol inhalation apparatus
US4570630A (en) Medicament inhalation device
US6718969B1 (en) Medication dosage inhaler system
US4821715A (en) Nasopharyngeal airway
Saketkhoo et al. Effects of drinking hot water, cold water, and chicken soup on nasal mucus velocity and nasal airflow resistance
US4484577A (en) Drug delivery method and inhalation device therefor
US6470882B1 (en) Pernasal application of aerosol medication
US4679555A (en) Method and apparatus for intrapulmonary delivery of heparin
US5027806A (en) Medication delivery system phase two
Barach et al. Inhalation of penicillin aerosol in patients with bronchial asthma, chronic bronchitis, bronchiectasis and lung abscess: preliminary report
US20100204602A1 (en) Nebulizer having flow meter function
US2763263A (en) Analgesic apparatus